Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 180 of 187 entries
Sorted by: Best Match Show Resources per page
Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices.

European urology oncology

van Stam MA, Aaronson NK, Bosch JLHR, Kieffer JM, van der Voort van Zyp JRN, Tillier CN, Horenblas S, van der Poel HG.
PMID: 31411965
Eur Urol Oncol. 2020 Feb;3(1):21-31. doi: 10.1016/j.euo.2018.12.004. Epub 2018 Dec 26.

BACKGROUND: Well-documented reports of patients' experiences with different treatments are important for helping localised prostate cancer (LPC) patients choose among the available treatment options.OBJECTIVE: To document differences in patient-reported outcomes (PROs) following radical prostatectomy (RP), external beam radiotherapy (EBRT),...

Deriving a preference-based utility measure for cancer patients from the European Organisation for the Research and Treatment of Cancer's Quality of Life Questionnaire C30: a confirmatory versus exploratory approach.

Patient related outcome measures

Costa DS, Aaronson NK, Fayers PM, Grimison PS, Janda M, Pallant JF, Rowen D, Velikova G, Viney R, Young TA, King MT.
PMID: 25395875
Patient Relat Outcome Meas. 2014 Nov 06;5:119-29. doi: 10.2147/PROM.S68776. eCollection 2014.

BACKGROUND: Multi attribute utility instruments (MAUIs) are preference-based measures that comprise a health state classification system (HSCS) and a scoring algorithm that assigns a utility value to each health state in the HSCS. When developing a MAUI from a...

Supporting Lung Cancer Patients With an Interactive Patient Portal: Feasibility Study.

JMIR cancer

Groen WG, Kuijpers W, Oldenburg HS, Wouters MW, Aaronson NK, van Harten WH.
PMID: 28790025
JMIR Cancer. 2017 Aug 08;3(2):e10. doi: 10.2196/cancer.7443.

BACKGROUND: MyAVL is an interactive portal for cancer patients that aims to support lung cancer patients.OBJECTIVE: We aimed to evaluate the feasibility and usability of the patient portal and generate preliminary evidence on its impact.METHODS: Lung cancer patients currently...

A systematic review of the measurement properties of the Body Image Scale (BIS) in cancer patients.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Melissant HC, Neijenhuijs KI, Jansen F, Aaronson NK, Groenvold M, Holzner B, Terwee CB, van Uden-Kraan CF, Cuijpers P, Verdonck-de Leeuw IM.
PMID: 29532245
Support Care Cancer. 2018 Jun;26(6):1715-1726. doi: 10.1007/s00520-018-4145-x. Epub 2018 Mar 12.

INTRODUCTION: Body image is acknowledged as an important aspect of health-related quality of life in cancer patients. The Body Image Scale (BIS) is a patient-reported outcome measure (PROM) to evaluate body image in cancer patients. The aim of this...

The Beginning of Trumpcare.

Clinical spine surgery

Sharan AD, Aaronson WE.
PMID: 28107232
Clin Spine Surg. 2017 Feb;30(1):30-31. doi: 10.1097/BSD.0000000000000497.

No abstract available.

The use of EORTC measures in daily clinical practice-A synopsis of a newly developed manual.

European journal of cancer (Oxford, England : 1990)

Wintner LM, Sztankay M, Aaronson N, Bottomley A, Giesinger JM, Groenvold M, Petersen MA, van de Poll-Franse L, Velikova G, Verdonck-de Leeuw I, Holzner B.
PMID: 27721057
Eur J Cancer. 2016 Nov;68:73-81. doi: 10.1016/j.ejca.2016.08.024. Epub 2016 Oct 06.

Cancer has increasingly become a chronic condition and the routine collection of patient-reported outcomes (PROs) like quality of life is widely recommended for clinical practice. Nonetheless, the successful implementation of PROs is still a major challenge, although common barriers...

Modeling intratumor heterogeneity through CRISPR-barcodes.

Molecular & cellular oncology

Guernet A, Aaronson SA, Anouar Y, Grumolato L.
PMID: 28090577
Mol Cell Oncol. 2016 Sep 06;3(6):e1227894. doi: 10.1080/23723556.2016.1227894. eCollection 2016.

We have devised a barcoding strategy to recapitulate cancer evolution through the emergence of subclonal mutations of interest, whose effects can be monitored in a dynamic manner. This approach can be easily adapted for a variety of applications, including...

AUTHOR REPLY.

Urology

Kwan ML, Danforth KN, Aaronson DS, Wagner MD, Williams SG, McMullen CK.
PMID: 30798971
Urology. 2019 Mar;125:229. doi: 10.1016/j.urology.2018.11.023.

No abstract available.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

British journal of cancer

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.
PMID: 29509747
Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 06.

This corrects the article DOI: 10.1038/bjc.2017.429.

NeuroExercise: The Effect of a 12-Month Exercise Intervention on Cognition in Mild Cognitive Impairment-A Multicenter Randomized Controlled Trial.

Frontiers in aging neuroscience

Stuckenschneider T, Sanders ML, Devenney KE, Aaronson JA, Abeln V, Claassen JAHR, Guinan E, Lawlor B, Meeusen R, Montag C, Olde Rikkert MGM, Polidori MC, Reuter M, Schulz RJ, Vogt T, Weber B, Kessels RPC, Schneider S.
PMID: 33519425
Front Aging Neurosci. 2021 Jan 14;12:621947. doi: 10.3389/fnagi.2020.621947. eCollection 2020.

Exercise intervention studies in mild cognitive impairment (MCI), a prodromal stage of Alzheimer's disease (AD), have demonstrated inconsistent yet promising results. Addressing the limitations of previous studies, this trial investigated the effects of a 12-month structured exercise program on...

Generalizability of Trial Data to Real-World Practice: An Analysis of The Society of Thoracic Surgeons Intermacs Database.

The Annals of thoracic surgery

Brescia AA, Watt TMF, Pagani FD, Cascino TM, Zhang M, McCullough JS, Shore S, Likosky DS, Aaronson KD, Cantor RS, Deng L, Kirklin JK, Thompson MP.
PMID: 34619136
Ann Thorac Surg. 2021 Oct 05; doi: 10.1016/j.athoracsur.2021.08.062. Epub 2021 Oct 05.

BACKGROUND: Although the current wide-scale adoption of the HeartMate 3 left ventricular assist device can be attributed to favorable clinical trial outcomes, restrictive clinical trial eligibility criteria may result in lack of generalizability to real-world populations. We assessed the...

Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.

Cancer discovery

Adamopoulos C, Ahmed TA, Tucker MR, Ung PMU, Xiao M, Karoulia Z, Amabile A, Wu X, Aaronson SA, Ang C, Rebecca VW, Brown BD, Schlessinger A, Herlyn M, Wang Q, Shaw DE, Poulikakos PI.
PMID: 33568355
Cancer Discov. 2021 Jul;11(7):1716-1735. doi: 10.1158/2159-8290.CD-20-1351. Epub 2021 Feb 10.

Current clinical RAF inhibitors (RAFi) inhibit monomeric BRAF (mBRAF) but are less potent against dimeric BRAF (dBRAF). RAFi equipotent for mBRAF and dBRAF have been developed but are predicted to have lower therapeutic index. Here we identify a third...

Showing 169 to 180 of 187 entries